mCHT inhibits the expression of pro-angiogenic factors, such as VEGF, VEGFR2, bFGF, and SDF1, and induces the production of angiogenesis inhibitors, such as thrombospondin-1, in both stromal and cancer cells, platelet factor-4, and endostatin. The gene discussed is KDR; the disease is cancer.